Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16123
Title: Targeting advanced glycation with pharmaceutical agents: where are we now?
Austin Authors: Borg, Danielle J;Forbes, Josephine M
Affiliation: Glycation and Diabetes, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Australia
Mater Clinical School, School of Medicine, University of Queensland, St Lucia, Queensland, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
Issue Date: Aug-2016
metadata.dc.date: 2016-07-09
Publication information: Glycoconjugate Journal 2016; 33(4): 653-70
Abstract: Advanced glycation end products (AGEs) are the final products of the Maillard reaction, a complex process that has been studied by food chemists for a century. Over the past 30 years, the biological significance of advanced glycation has also been discovered. There is mounting evidence that advanced glycation plays a homeostatic role within the body and that food-related Maillard products, intermediates such as reactive α-dicarbonyl compounds and AGEs, may influence this process. It remains to be understood, at what point AGEs and their intermediates become pathogenic and contribute to the pathogenesis of chronic diseases that inflict current society. Diabetes and its complications have been a major focus of AGE biology due to the abundance of excess sugar and α-dicarbonyls in this family of diseases. While further temporal information is required, a number of pharmacological agents that inhibit components of the advanced glycation pathway have already showed promising results in preclinical models. These therapies appear to have a wide range of mechanistic actions to reduce AGE load. Some of these agents including Alagebrium, have translated successfully to clinical trials, while others such as aminoguanidine, have had undesirable side-effect profiles. This review will discuss different pharmacological agents that have been used to reduce AGE burden in preclinical models of disease with a focus on diabetes and its complications, compare outcomes of those therapies that have reached clinical trials, and provide further rationale for the use of inhibitors of the glycation pathway in chronic diseases.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16123
DOI: 10.1007/s10719-016-9691-1
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27392438
Type: Journal Article
Subjects: Advanced glycation end products
Advanced glycation pathway
Alagebrium
Aminoguanidine
Diabetes
Diabetes complications
Maillard reaction
Methylglyoxal
Pyridoxamine
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.